keyword
https://read.qxmd.com/read/38537032/direct-aortic-cannulation-versus-femoral-arterial-cannulation-for-early-outcomes-in-acute-type-a-aortic-dissection-a-study-level-meta-analysis
#1
REVIEW
Yoshiyuki Yamashita, Serge Sicouri, Stephanie Kjelstrom, Georgia Montone, Aleksander Dokollari, Khalid Ridwan, Nicholas Clarke, Roberto Rodriguez, Scott M Goldman, Basel Ramlawi
PURPOSE: To investigate the impact of direct aortic cannulation (DAC) versus femoral arterial cannulation (FAC) on clinical outcomes of surgery for acute type A aortic dissection. METHODS: PubMed/MEDLINE, Scopus, and Cochrane Central Register of Controlled Trials were searched until August 25, 2023, to conduct a meta-analysis. Primary endpoints of the study were operative mortality and postoperative stroke. Secondary endpoints were cardiopulmonary bypass time, myocardial ischemic time, hypothermic circulatory arrest time, temporary neurological dysfunction (TND), combined stroke and TND, re-exploration for bleeding, and need for renal replacement therapy...
March 27, 2024: Perfusion
https://read.qxmd.com/read/38537025/effects-of-an-early-intensive-blood-pressure-lowering-strategy-using-remifentanil-and-dexmedetomidine-in-patients-with-spontaneous-intracerebral-hemorrhage-a-multicenter-prospective-superiority-randomized-controlled-trial
#2
JOURNAL ARTICLE
Rui Dong, Fen Li, Bin Li, Qiming Chen, Xianjian Huang, Jiehua Zhang, Qibing Huang, Zeli Zhang, Yunxing Cao, Mingbiao Yang, Jianwei Li, Zhanfu Li, Cuiyu Li, Guohua Liu, Shu Zhong, Guang Feng, Ming Zhang, Yumei Xiao, Kangyue Lin, Yunlong Shen, Huanzhang Shao, Yuan Shi, Xiangyou Yu, Xiaopeng Li, Lan Yao, Xinyu Du, Ying Xu, Pei Kang, Guoyi Gao, Bin Ouyang, Wenjin Chen, Zhenhua Zeng, Pingyan Chen, Chunbo Chen, Hong Yang
BACKGROUND: Although it has been established that elevated blood pressure and its variability worsen outcomes in spontaneous intracerebral hemorrhage, antihypertensives use during the acute phase still lacks robust evidence. A blood pressure-lowering regimen using remifentanil and dexmedetomidine might be a reasonable therapeutic option given their analgesic and anti-sympathetic effects. The objective of this superiority trial was to validate the efficacy and safety of this blood pressure-lowering strategy that uses remifentanil and dexmedetomidine in patients with acute intracerebral hemorrhage...
March 27, 2024: Anesthesiology
https://read.qxmd.com/read/38536218/views-of-service-users-their-family-or-carers-and-health-care-professionals-on-telerehabilitation-for-people-with-neurological-conditions-in-ghana-qualitative-study
#3
JOURNAL ARTICLE
Lorna Paul, Katie Thomson, Shadrack Osei Asibey, Marian Brady, Frederike van Wijck, Derrick Antwi, Eric Nkansah Opoku, Fred Stephen Sarfo
BACKGROUND: Up to 50% of people in low- and middle-income countries do not receive the rehabilitation they require. Telerehabilitation has the potential to improve access to neurorehabilitation services especially in low- and middle-income countries. Although there are reports of the barriers and facilitators to telerehabilitation in such settings, almost all are anecdotal. Furthermore, family or carers have a significant influence on the adoption and success of telerehabilitation, but their views have not been reported...
March 27, 2024: JMIR MHealth and UHealth
https://read.qxmd.com/read/38534532/electric-field-characteristics-of-rotating-permanent-magnet-stimulation
#4
JOURNAL ARTICLE
Pei L Robins, Sergey N Makaroff, Michael Dib, Sarah H Lisanby, Zhi-De Deng
Neurostimulation devices that use rotating permanent magnets are being explored for their potential therapeutic benefits in patients with psychiatric and neurological disorders. This study aims to characterize the electric field (E-field) for ten configurations of rotating magnets using finite element analysis and phantom measurements. Various configurations were modeled, including single or multiple magnets, and bipolar or multipolar magnets, rotated at 10, 13.3, and 350 revolutions per second (rps). E-field strengths were also measured using a hollow sphere (r=9...
March 6, 2024: Bioengineering
https://read.qxmd.com/read/38533819/bruton-tyrosine-kinase-inhibitors-in-multiple-sclerosis-evidence-and-expectations
#5
JOURNAL ARTICLE
Julia Krämer, Heinz Wiendl
PURPOSE OF REVIEW: Despite availability of high-efficacy therapies for multiple sclerosis (MS), many patients experience significant disability worsening due to limited effects of currently available drugs on central nervous system (CNS)-compartmentalized inflammation. Bruton tyrosine kinase (BTK) is an intracellular signaling molecule involved in regulation of maturation, survival, migration, and activation of B cells and microglia, which are central players in the immunopathogenesis of progressive MS...
March 28, 2024: Current Opinion in Neurology
https://read.qxmd.com/read/38532803/sex-differences-in-multiple-sclerosis-relapse-presentation-and-outcome-a-retrospective-monocentric-study-of-134-relapse-events
#6
JOURNAL ARTICLE
Pauline Thränhardt, Admirim Veselaj, Christoph Friedli, Franca Wagner, Stefanie Marti, Lara Diem, Helly Hammer, Piotr Radojewski, Roland Wiest, Andrew Chan, Robert Hoepner, Anke Salmen
BACKGROUND: Reporting of sex-specific analyses in multiple sclerosis (MS) is sparse. Disability accrual results from relapses (relapse-associated worsening) and independent thereof (progression independent of relapses). OBJECTIVES: A population of MS patients during relapse treated per standard of care was analyzed for sex differences and short-term relapse outcome (3-6 months) as measured by Expanded Disability Status Scale (EDSS) change. DESIGN: Single-center retrospective study...
2024: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38532733/characterization-of-fine-motor-and-visual-motor-skills-in-aicardi-gouti%C3%A3-res-syndrome
#7
JOURNAL ARTICLE
Stacy V Cusack, Francesco Gavazzi, Isabella Peixoto de Barcelos, Nicholson B Modesti, Sarah Woidill, Brielle Formanowski, Sara B DeMauro, Scott Lorch, Ariel Vincent, Abbas F Jawad, Timothy Estilow, Allan M Glanzman, Adeline Vanderver, Laura A Adang
Aicardi-Goutières syndrome is a genetic inflammatory disorder resulting in dispersed neurologic dysfunction. Despite a recognition of overall motor impairment, fine and visual motor skills are undercharacterized. We hypothesize that there is a spectrum of fine and visual motor skills in the Aicardi-Goutières syndrome population as captured by a standard outcome measure, the Peabody Developmental Motor Scales (PDMS-2), which will be proportional to overall disease severity.In a cohort of 74 subjects, the Peabody Developmental Motor Scales-2 grasping and visual-motor integration subtests were administered concurrently with the Aicardi-Goutières syndrome Severity Scale (severe [range 0-3], moderate [range 4-8], and attenuated [range 9-11])...
March 27, 2024: Journal of Child Neurology
https://read.qxmd.com/read/38532142/efgartigimod-in-the-treatment-of-guillain-barr%C3%A3-syndrome
#8
JOURNAL ARTICLE
Huiqiu Zhang, Jing Ma, Yingna Feng, Hui Ma, Dan Liu, Xiaomin Pang, Xueli Chang, Rongjuan Zhao, Juan Wang, Junhong Guo, Wei Zhang
BACKGROUND: Guillain-Barré Syndrome (GBS) is caused by immunoglobulin G (IgG) autoantibodies. Efgartigimod, a human IgG antibody Fc fragment that acts as a natural ligand for the FcRn, can increase IgG degradation, which thus may be a promising therapeutic drug for GBS. CASE PRESENTATION: The two patients presented with postinfectious and acute flaccid paralysis. On admission, they were bedridden. Nerve conduction studies indicated peripheral neuropathy. GBS was suspected and they are treated with two doses of efgartigimod (10 mg/kg) within 5 days...
March 26, 2024: Journal of Neurology
https://read.qxmd.com/read/38531575/survival-and-neurological-function-in-patients-treated-with-extracorporeal-membrane-oxygenation-and-therapeutic-hypothermia-a-protocol-for-updating-a-systematic-review
#9
JOURNAL ARTICLE
Pengfei Cheng, Haizhen Wang, Luyao Guo, Meiling Wang, He Xu, Peipei Gu, Jinjing Wu, Minfei Yang
INTRODUCTION: The widespread application of extracorporeal membrane oxygenation (ECMO) has enhanced clinical outcomes for patients experiencing cardiac arrest. However, its effectiveness is still limited and falls short of the desired level. Therapeutic hypothermia, which maintains body temperatures between 32°C and 36°C in cardiac arrest patients treated with ECMO, has been proposed as a potential means of neuroprotection and increased survival rates. Nevertheless, it remains controversial, and its impact on patient complications has yet to be fully understood...
March 25, 2024: BMJ Open
https://read.qxmd.com/read/38531163/natural-history-of-neuronal-ceroid-lipofuscinosis-type-6-late-infantile-disease
#10
JOURNAL ARTICLE
Matthew O'Neal, Ines Noher de Halac, Shawn C Aylward, Vedat Yildiz, Bianca Zapanta, Nicolas Abreu, Emily de Los Reyes
BACKGROUND: Mutations in the CLN6 gene cause late infantile neuronal ceroid lipofuscinosis, a neurodegenerative lysosomal storage disease of childhood onset. Clinically, individuals present with progressive motor and cognitive regression, ataxia, and early death. The aim of this study is to establish natural history data of individuals with classic, late-infantile-onset (age less than five years) CLN6 disease. METHODS: We analyzed the natural history of 25 patients with late-infantile-onset CLN6, utilizing the Hamburg motor-language scale to measure disease progression...
March 1, 2024: Pediatric Neurology
https://read.qxmd.com/read/38531017/clinical-characteristics-developmental-trajectory-and-caregiver-burden-of-patients-with-creatine-transporter-deficiency-slc6a8
#11
JOURNAL ARTICLE
Aurore Curie, Laurence Lion-François, Vassili Valayannopoulos, Nathalie Perreton, Marie Gavanon, Nathalie Touil, Amandine Brun-Laurisse, Fahra Gheurbi, Marion Buchy, Hulya Halep, David Cheillan, Catherine Mercier, Anaïs Brassier, Béatrice Desnous, Behrouz Kassai, Pascale De Lonlay, Vincent Des Portes
BACKGROUND AND OBJECTIVES: Creatine transporter deficiency (CTD) is a rare X-linked genetic disorder characterized by intellectual disability (ID). We evaluated the clinical characteristics and trajectory of patients with CTD and the impact of the disease on caregivers to identify relevant endpoints for future therapeutic trials. METHODS: As part of a French National Research Program, patients with CTD were included based on (1) a pathogenic SLC6A8 variant and (2) ID and/or autism spectrum disorder...
April 23, 2024: Neurology
https://read.qxmd.com/read/38531004/iv-thrombolysis-in-basilar-artery-occlusion-outcomes-and-comparison-with-endovascular-thrombectomy
#12
JOURNAL ARTICLE
Silja Räty, Pekka Virtanen, Juhani Ritvonen, Georgios Georgiopoulos, Tiina Sairanen, Perttu J Lindsberg, Daniel Strbian
BACKGROUND AND OBJECTIVES: Recanalization is considered a prerequisite for favorable outcome in basilar artery occlusion (BAO). Intravenous thrombolysis (IVT) has been successfully used for eligible patients with BAO well beyond the 4.5-hour time window but has been largely underrepresented in the best medical management arms in recent randomized controlled trials of recanalization therapy in BAO. We aimed to analyze the outcomes of patients with BAO treated with IVT only and to compare IVT with endovascular thrombectomy (EVT)...
April 23, 2024: Neurology
https://read.qxmd.com/read/38529039/therapeutic-potential-to-target-sialylation-and-siglecs-in-neurodegenerative-and-psychiatric-diseases
#13
REVIEW
Jannis Wißfeld, Tawfik Abou Assale, German Cuevas-Rios, Huan Liao, Harald Neumann
Sialic acids, commonly found as the terminal carbohydrate on the glycocalyx of mammalian cells, are pivotal checkpoint inhibitors of the innate immune system, particularly within the central nervous system (CNS). Sialic acid-binding immunoglobulin-like lectins (SIGLECs) expressed on microglia are key players in maintaining microglial homeostasis by recognizing intact sialylation. The finely balanced sialic acid-SIGLEC system ensures the prevention of excessive and detrimental immune responses in the CNS. However, loss of sialylation and SIGLEC receptor dysfunctions contribute to several chronic CNS diseases...
2024: Frontiers in Neurology
https://read.qxmd.com/read/38529035/disease-modifying-therapy-in-progressive-multiple-sclerosis-a-systematic-review-and-network-meta-analysis-of-randomized-controlled-trials
#14
Xin Wu, Shixin Wang, Tao Xue, Xin Tan, Jiaxuan Li, Zhouqing Chen, Zhong Wang
BACKGROUND: Currently, disease-modifying therapies (DMTs) for progressive multiple sclerosis (PMS) are widely used in clinical practice. At the same time, there are a variety of drug options for DMTs, but the effect of the drugs that can better relieve symptoms and improve the prognosis are still inconclusive. OBJECTIVES: This systematic review aimed to evaluate the efficacy and safety of DMTs for PMS and to identify the best among these drugs. METHODS: MEDLINE, EMBASE, the Cochrane Library, and clinicaltrials...
2024: Frontiers in Neurology
https://read.qxmd.com/read/38528163/real-world-experience-with-efgartigimod-in-patients-with-myasthenia-gravis
#15
JOURNAL ARTICLE
Lior Fuchs, Shahar Shelly, Ifat Vigiser, Hadar Kolb, Keren Regev, Yoel Schwartzmann, Adi Vaknin-Dembinsky, Amir Dori, Arnon Karni
Recommendations for the treatment of myasthenia gravis (MG) have been difficult to develop because of limited evidence from large randomized controlled trials. New drugs and treatment approaches have recently been shown to be effective in phase 3 studies in seropositive generalized (g) MG. One such drug is efgartigimod, a human-Fc-fragment of IgG1, with a high affinity for the endosomal FcRn. We conducted a multicenter study to evaluate the real-world clinical and safety effects of efgartigimod in 22 gMG patients...
March 25, 2024: Journal of Neurology
https://read.qxmd.com/read/38527298/artificial-intelligence-based-video-monitoring-of-movement-disorders-in-the-elderly-a-review-on-current-and-future-landscapes
#16
JOURNAL ARTICLE
Kye Won Park, Maryam S Mirian, Martin J McKeown
Due to global ageing, the burden of chronic movement and neurological disorders (Parkinson's disease and essential tremor) is rapidly increasing. Current diagnosis and monitoring of these disorders rely largely on face-to-face assessments utilising clinical rating scales, which are semi-subjective and time-consuming. To address these challenges, the utilisation of artificial intelligence (AI) has emerged. This review explores the advantages and challenges associated with using AI-driven video monitoring to care for elderly patients with movement disorders...
March 1, 2024: Singapore Medical Journal
https://read.qxmd.com/read/38526612/a-muscarinic-receptor-antagonist-reverses-multiple-indices-of-diabetic-peripheral-neuropathy-preclinical-and-clinical-studies-using-oxybutynin
#17
RANDOMIZED CONTROLLED TRIAL
Carolina M Casselini, Henri K Parson, Katie E Frizzi, Alex Marquez, Darrell R Smith, Lucie Guernsey, Rakesh Nemmani, Alireza Tayarani, Corinne G Jolivalt, Jessica Weaver, Paul Fernyhough, Aaron I Vinik, Nigel A Calcutt
Preclinical studies indicate that diverse muscarinic receptor antagonists, acting via the M1 sub-type, promote neuritogenesis from sensory neurons in vitro and prevent and/or reverse both structural and functional indices of neuropathy in rodent models of diabetes. We sought to translate this as a potential therapeutic approach against structural and functional indices of diabetic neuropathy using oxybutynin, a muscarinic antagonist approved for clinical use against overactive bladder. Studies were performed using sensory neurons maintained in vitro, rodent models of type 1 or type 2 diabetes and human subjects with type 2 diabetes and confirmed neuropathy...
March 25, 2024: Acta Neuropathologica
https://read.qxmd.com/read/38526543/use-of-lcp-tacrolimus-lcpt-in-kidney-transplantation-a-delphi-consensus-survey-of-expert-clinicians
#18
JOURNAL ARTICLE
Alexander Wiseman, Tarek Alhamad, Rita R Alloway, Beatrice P Concepcion, Matthew Cooper, Richard Formica, Christina L Klein, Vineeta Kumar, Nicolae Leca, Fuad Shihab, David J Taber, Sarah Mulnick, Donald M Bushnell, Monica Hadi, Suphamai Bunnapradist
BACKGROUND LCPT (Envarsus XR®) is a common once-daily, extended-release oral tacrolimus formulation used in kidney transplantation. However, there are minimal evidence-based recommendations regarding optimal dosing and treatment in the de novo and conversion settings. MATERIAL AND METHODS Using Delphi methodology, 12 kidney transplantation experts with LCPT experience reviewed available data to determine potential consensus topics. Key statements regarding LCPT use were generated and disseminated to the panel in an online Delphi survey...
March 12, 2024: Annals of Transplantation: Quarterly of the Polish Transplantation Society
https://read.qxmd.com/read/38526462/high-efficacy-therapy-discontinuation-vs-continuation-in-patients-50-years-and-older-with-nonactive-ms
#19
JOURNAL ARTICLE
Guillaume Jouvenot, Guilhem Courbon, Mathilde Lefort, Fabien Rollot, Romain Casey, Emmanuelle Le Page, Laure Michel, Gilles Edan, Jérome de Seze, Laurent Kremer, Kevin Bigaut, Sandra Vukusic, Guillaume Mathey, Jonathan Ciron, Aurélie Ruet, Elisabeth Maillart, Pierre Labauge, Hélène Zephir, Caroline Papeix, Gilles Defer, Christine Lebrun-Frenay, Thibault Moreau, David Axel Laplaud, Eric Berger, Bruno Stankoff, Pierre Clavelou, Eric Thouvenot, Olivier Heinzlef, Jean Pelletier, Abdullatif Al-Khedr, Olivier Casez, Bertrand Bourre, Philippe Cabre, Abir Wahab, Laurent Magy, Jean-Philippe Camdessanché, Ines Doghri, Solène Moulin, Haifa Ben-Nasr, Céline Labeyrie, Karolina Hankiewicz, Jean-Philippe Neau, Corinne Pottier, Chantal Nifle, Nicolas Collongues, Anne Kerbrat
IMPORTANCE: A recent randomized clinical trial concluded that discontinuing medium-efficacy therapy might be a reasonable option for older patients with nonactive multiple sclerosis (MS), but there is a lack of data on discontinuing high-efficacy therapy (HET). In younger patients, the discontinuation of natalizumab and fingolimod is associated with a risk of rebound of disease activity. OBJECTIVE: To determine whether discontinuing HET in patients 50 years and older with nonactive MS is associated with an increased risk of relapse compared with continuing HET...
March 25, 2024: JAMA Neurology
https://read.qxmd.com/read/38526461/early-use-of-erenumab-vs-nonspecific-oral-migraine-preventives-the-appraise-randomized-clinical-trial
#20
JOURNAL ARTICLE
Patricia Pozo-Rosich, David Dolezil, Koen Paemeleire, Adam Stepien, Philipp Stude, Josefin Snellman, Michal Arkuszewski, Tracy Stites, Shannon Ritter, Cristina Lopez Lopez, Jeff Maca, Matias Ferraris, Raquel Gil-Gouveia
IMPORTANCE: Patients with migraine often cycle through multiple nonspecific preventive medications due to poor tolerability and/or inadequate efficacy leading to low adherence and increased disease burden. OBJECTIVE: To compare the efficacy, tolerability, patient adherence, and patient satisfaction between erenumab and nonspecific oral migraine preventive medications (OMPMs) in patients with episodic migraine (EM) who had previously failed 1 or 2 preventive treatments...
March 25, 2024: JAMA Neurology
keyword
keyword
166722
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.